Navigation Links
Genetic Pathways to Curable and Incurable Forms of Pancreatic Cancer Identified

Pancreatic ductal adenocarcinoma is an almost uniformly fatal disease regardless of the stage at time of diagnosis. However, a small percentage //of patients develop a form of ductal adenocarcinoma associated with cystic lesions that can be detected earlier, is less aggressive and has a 50 percent long-term survival rate. Why cystic ductal pancreatic cancer behaves differently, despite carrying the same basic genetic mutations as the more common and deadly type of ductal pancreatic cancer, has long been a mystery. Now researchers at Fred Hutchinson Cancer Research Center have unlocked the genetic reason why.

Using unique mouse models to mimic the progression of both forms of human pancreatic cancer, researchers have discovered that a specific sequence of otherwise common genetic mutations is responsible for sending cells down the less-traveled path toward cystic pancreatic cancer versus the well-traveled route to the more fatal form of ductal pancreatic cancer.

Sunil Hingorani, M.D., assistant member of the Hutchinson Center's Clinical Research and Public Health Sciences divisions, led a study to be published in the March 12 issue of the journal Cancer Cell that explains this sequence and details why the cells behave differently.

"Although at their end stage the two different routes to ductal pancreatic cancer can look very much the same under the microscope, involve the same constellation of genetic events, and culminate in invasive and metastatic disease that can ultimately kill patients, one route is 100 percent fatal while the other is 50 percent curable," Hingorani said. "Until now we didn't understand why. What these studies suggest is that it's not just the total complement of mutations that determines the behavior of these cancers but also the sequence in which the mutations arise."

About 5 percent of all primary tumors of the pancreas, out of 40,000 annual new cases in the United States, arise from cystic t umors.

The findings reported in the journal by Hingorani and colleagues represent an accidental discovery. The researchers started out studying the common genetic pathways to pancreatic ductal adenocarcinoma in hopes of finding clues to developing early detection biomarkers and possible treatments to halt the progression of the disease. The work involved activating the pancreatic cancer oncogene called Kras and then selectively mutating tumor-suppressor genes such as p53, p16 and Dpc4 in different combinations.

In the mouse model, which Hingorani first developed while at the University of Pennsylvania, the combination of Kras and p53 led to the more deadly form of pancreatic ductal adenocarcinoma. Earlier studies by researchers in Boston also found the same association between Kras and p16. From studies of human cancers, it is known that mutations in Dpc4 can also occur, but they do so late in the course of disease progression. The current study showed that the combination of Kras and an early mutation of Dcp4, in which one copy of the suppressor gene is eliminated, lead to cancer by a different path, beginning with the creation of a distinct class of precancerous lesions in the ductal epithelium called mucinous cystic neoplasms (MCN). This initiates a process that results in the rarer but far less deadly cystic pancreatic cancer.

MCN lesions often are large enough to be detected early by MRI or CT scan and also to cause symptoms. The cells in this cancer also react differently to a key signaling protein, TGFb, which can induce cancer cells to change shape and become more mobile and invasive. It turns out that the cystic pancreatic cancer cells are resistant to these effects of TGFb and these types of cancers are also less likely to invade surrounding tissues and to metastasize, or spread, to other organs. These properties likely contribute to the improved survival seen with this form of the cancer, Hingorani said.

Conversely, the initial lesions that lead to the more common and deadly form of pancreatic ductal adenocarcinoma, called pancreatic epithelial neoplasms, are tiny enough to be undetectable until the disease has progressed to the point where survival is almost nil. Moreover, these cells appear to be highly sensitive to the tumor-promoting properties of TGFb and thereby manifest a more aggressive behavior.

"With accurate animal models of both forms of pancreatic ductal cancers now in hand, it should be possible to unravel the detailed mechanisms behind their distinct behavior and hopefully identify points of vulnerability in the more fatal form to improve survival," Hingorani said.

Source-Eurekalert
'"/>




Related medicine news :

1. Genetic Dentistry: Your Dentist may be able to grow you a new set of Teeth.
2. Genetic influence in menopause
3. Genetics and cholesterol levels
4. Genetics helps in attacking cancer
5. Genetic disorder related with sleep patterns
6. Genetic innovation
7. Genetic tests for cancer
8. Genetic indicates memory
9. Genetic mutation to the fountain of youth discovered
10. Genetic differences found between Male and Female brains
11. Alcoholism Influenced By Both Genetics & Family Environment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... June 23, 2017 , ... Ulster University, Magee Campus ... from 9 am to 3 pm to present to graduate students exciting new and ... an original curriculum project led by The Health Improvement Service of the Western Health ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, ... families and business owners in North Central West Virginia, is embarking on a ... differently abled residents in the region. , The Stepping Stones organization offers a ...
(Date:6/22/2017)... Indianapolis, IN (PRWEB) , ... June 22, 2017 ... ... employee benefits advisory organization, is pleased to welcome Whipple & Company as its ... on the clear purpose of balancing their clients’ risk while tailoring optimized benefit ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... awards for environmental excellence. Maryland Recycling Network has awarded the Baltimore VA Medical ... Outstanding Small Government Program Award for its efforts to promote waste reduction and ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... that Claritas Capital, a Nashville-based private equity firm, has invested $3.35 million in ... for some time, and Claritas Capital offers the smart money, speed to market ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 8, 2017  Less than a month ago, amateur ... 200,000 companies, including hospital networks, in over 150 countries. ... of the largest online extortion attempts ever recorded. With ... it is imperative that providers understand where the risks ... this — and many other very real cyber threats.  ...
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: